Back to Journals » Stem Cells and Cloning: Advances and Applications » Volume 15

A Response to Article “Hypoxia Effects in Intervertebral Disc-Derived Stem Cells and Discus Secretomes: An in vitro Study” [Letter]

Authors Rinendyaputri R , Noviantari A , Lienggonegoro LA 

Received 23 September 2022

Accepted for publication 30 September 2022

Published 20 October 2022 Volume 2022:15 Pages 63—64

DOI https://doi.org/10.2147/SCCAA.S391016

Checked for plagiarism Yes

Editor who approved publication: Dr Bernard Binetruy



Ratih Rinendyaputri *, Ariyani Noviantari *, Lisa Andriani Lienggonegoro *

Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency, Cibinong, West Java, Indonesia

*These authors contributed equally to this work

Correspondence: Lisa Andriani Lienggonegoro, Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency, Genomic Building, Cibinong Science Center, Jl. Raya Bogor Km 46, Cibinong, West Java, Indonesia, Email [email protected]


View the original paper by Dr Romaniyanto and colleagues


Dear Editor

We appreciate the authors who have reported their research in “Hypoxia Effects in Intervertebral Disc-Derived Stem Cells and Discus Secretomes: An in vitro Study”, published in Stem cells and Cloning: Advances and Applications 2022;15:21–28. This is very important information about hypoxic preconditioning in mesenchymal stem cells/MSC for degenerative disease therapy.1

In this study, the authors reported that 3% oxygen (O2) levels could increase the secretion of growth factors, especially fibroblast growth factor/FGF and platelet-derived growth factor/PDGF, meanwhile, increased secretion of transforming growth factor/TGF-β1 needed higher oxygen level (5%). These findings indicated that MSC could secrete various growth factors according to environmental conditions, including oxygen levels or hypoxic preconditioning. This means that O2 levels can facilitate MSC to produce growth factors according to specific purposes. For example, TGF-β1 acted as an immunosuppressant to overcome inflammation and accelerate cell regeneration.2 However, if the experiment goal was to increase cell proliferation which is strongly influenced by FGF and PDGF, then hypoxia 3% O2 is recommended.

Stem cells in this study were isolated from intervertebral disc-derived stem cells/IVDS. Currently, many researchers are interested in the potential of IVDS to address the degeneration problem in the intervertebral disc. Unfortunately, this study did not report the characterization of their stem cells, therefore we could not precisely estimate the purity of stem cells in the cell population. Characterization of stem cells could provide information about the type of stem cells that produced these growth factors (FGF, PDGF, VEGF, and TGF- β1).

Other studies have reported that cytokines and growth factors secretion from MSCs originating from gingival, adipose tissue, umbilical cord or Wharton’s jelly tend to increase in a hypoxic microenvironment.3–5 Upregulation of pro and anti-inflammatory cytokines and chemokines can certainly be used as immunomodulators.5 Increased neurotrophic factor would be very beneficial for nerve cell regeneration.3

More information about the sources of stem cells, and the methods of obtaining the secretome containing cytokines, chemokines, and growth factors, they would be very useful as evidence for translational research from in vitro and pre-clinical research toward clinical trial settings.

Acknowledgments

We would like to thank Dr. Sunarno for his suggestions and advice, we also appreciate all of the support given to the authors throughout the preparation of the article.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Romaniyanto MF, Prakoeswa CRS, Notobroto HB, et al. Hypoxia effects in intervertebral disc-derived stem cells and discus secretomes: an in vitro study. Stem Cells Cloning Adv Appl. 2022;15:21–28. doi:10.2147/SCCAA.S363951

2. Bavarsad SS, Jalali MT, Nejad DB, Alypoor B, Rezaei HB, Mohammadtaghvaei N. TGFβ1-pretreated exosomes of Wharton jelly mesenchymal stem cell as a therapeutic strategy for improving liver fibrosis. Hepat Mon. 2022;22(1):1–12. doi:10.5812/hepatmon-123416

3. Patil S, Fageeh HN, Fageeh HI, et al. Hypoxia, a dynamic tool to amplify the gingival mesenchymal stem cells potential for neurotrophic factor secretion. Saudi J Biol Sci. 2022;29(5):3568–3576. doi:10.1016/j.sjbs.2022.02.039

4. Laksmitawati DR, Widowati W, Noverina R, et al. Production of inflammatory mediators in conditioned medium of adipose tissue-derived mesenchymal stem cells (ATMSC)-treated fresh frozen plasma. Med Sci Monit Basic Res. 2022;28:e933726. doi:10.12659/msmbr.933726

5. Chouw A, Sartika CR, Milanda T, Faried A. Interleukins profiling in umbilical cord mesenchymal stem cell-derived secretome. Stem Cells Cloning Adv Appl. 2022;15:1–9. doi:10.2147/SCCAA.S356763

Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.